Business Wire

Kymeta Provided High-Speed Mobile Internet Access to Puerto Rico During Recovery Efforts

Jaa

Kymeta—the communications company making good on the promise of global, mobile connectivity—partnered with Intelsat and Liberty Puerto Rico to reconnect communities across Puerto Rico when communications and power were severed by Hurricane Maria.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180313005612/en/

Kymeta, along with partners Intelsat and Liberty Puerto Rico, traveled to 33 communities across Puer ...

Kymeta, along with partners Intelsat and Liberty Puerto Rico, traveled to 33 communities across Puerto Rico in the aftermath of Hurricane Maria, providing 22,266 internet sessions and 813.44GB data usage to impacted residents. (Photo: Business Wire)

Three Kymeta-enabled vehicles joined a disaster relief caravan that crisscrossed the island of Puerto Rico from October through December 2017*. The vehicles were equipped with Kymeta KyWay™ flat panel, beam-forming, electronically-steered satellite terminals. Despite the lack of any electrical power or cellular service, the low power-consuming terminals provided internet access using the vehicles to power the communications system.

“The tour provided communication capabilities for disaster relief efforts and brought high-speed connectivity to communities that were without power or communications for weeks,” said Naji Khoury, President, Liberty Puerto Rico. Overall, the Liberty Puerto Rico Wi-Fi Tour delivered 22,266 internet sessions and 813.44GB of data usage. “This internet access supported relief efforts in 33 communities, supporting public safety staff and helping residents access much-needed funds from pop-up ATMs, fill prescriptions and file 2,504 FEMA applications,” continued Khoury. “For many of the residents, it was also the first time they had the opportunity to communicate with friends and family since the hurricane.”

For Kymeta, providing much-needed communications in the wake of a disaster made sense.

“The Liberty Puerto Rico team has worked tirelessly over the last several months to provide some level of normalcy for the island,” said Nathan Kundtz, PhD., Founder, President and CEO, Kymeta. “Being without communications is one of the most common issues for residents, first responders and ongoing disaster relief efforts following a natural disaster.” Lack of communication is also the biggest roadblock to providing a fast and effective response to a natural disaster or an emergency. “Providing communications where it otherwise wouldn’t exist means limited resources can be sent where they will make the greatest impact,” said Kundtz. “We have been privileged to support the efforts in Puerto Rico.”

In addition to offering high-speed internet access, the tour concluded with 36,895 hot meals served and 4,213 medical services, including vaccinations, rendered.

*During the Liberty Puerto Rico Wi-Fi Tour, Kymeta and its partners visited 33 of the most significantly impacted communities across Puerto Rico: Corozal, Toa Baja, Comerio, Naranjito, Barranquitas, Naguabo, Vega Baja, Florida, Arecibo, Cayey, Humacao, Fajardo, Ceiba, Yabucoa, Guayama, Salinas, Utuado, Ciales, Orocovis, Jayuya, Villalba, Coamo, Juana Díaz, Santa Isabel, Maricao, Las Marías, Moca, Lares, Morovis, Aguas Buenas, Patillas, Maunabo and Yaucao.

About Kymeta

The world’s demand for ubiquitous mobile connectivity is irrefutable. A global, mobile network is the answer to connecting people and places that have never been connected before.

Kymeta is making seamless, always-connected mobile communications possible with a unique hybrid approach that enables satellite and cellular networks to together deliver a single, global, mobile network. End-to-end mobile communications are delivered with Kymeta KĀLO™ connectivity services, and the world’s first electronically-steered, flat panel satellite terminal that goes places traditional satellite dishes cannot. The Kymeta KyWay™ terminal makes high-throughput, mobile communications possible in cars, trains, buses, trucks, boats and much more.

If it moves, Kymeta keeps it connected.

For more information, visit kymetacorp.com and KALO.net.

Contact information

Business Inquiries for Kymeta:
Kymeta Corporation
Lisa Dreher, +1 425-658-8724
Director of Marketing
ldreher@kymetacorp.com
or
Media Inquiries for Kymeta:
The Summit Group
Amy Oliver, +1 801-990-1185
PR/Content Manager
aoliver@summitslc.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45Tiedote

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10Tiedote

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30Tiedote

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 20:37Tiedote

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10Tiedote

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme